RSS Feed ALL

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

1 day ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

4 days ago

• Expanded U.S. availability paired with new patient lifestyle quiz encourages informed...

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

4 days ago

· Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant...

DePuy Synthes Launches VELYS™ Hip Navigation with AI to Support Intraoperative Consistency and Efficiency in Total Hip Arthroplasty

6 days ago

Use of VELYS™ Hip Navigation with AI Assistance demonstrated reproducible landmark identification...

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

7 days ago

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of...

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

12 days ago

· Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker...

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren’s disease

12 days ago

· Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to...

Johnson & Johnson Phase 3 prostate cancer study shows ERLEADA®(apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

15 days ago

• Patients were nine times more likely to have little to no...

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

15 days ago

• More than one-third of responders with previously treated disease achieved complete...

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

16 days ago

• Median overall survival, a secondary endpoint, reached nearly 3.5 years with...

New TECVAYLI® data demonstrates superior progression-free and overall survival as early as first relapse in multiple myeloma

17 days ago

• Building on the recent approval of TECVAYLI®plus DARZALEX FASPRO®,MajesTEC-9 is the...

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

17 days ago

TREMFYA® showed significant inhibition of structural joint damage in adults with active...